| Literature DB >> 7400825 |
Abstract
Clinicians treating patients with myasthenia gravis must choose cholinergic drugs, corticosteroids, immunosuppressive drugs, thymectomy, or plasmapheresis. Clinicians must decide the sequence or combination of these therapies and when to deem lack of improvement a sign for a different therapeutic approach. Because controlled trials have not been done to evaluate therapies that may require months or years before benefit is evident, controversy abounds.Entities:
Mesh:
Substances:
Year: 1980 PMID: 7400825 PMCID: PMC490631 DOI: 10.1136/jnnp.43.7.644
Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN: 0022-3050 Impact factor: 10.154